The FilterWire EZTM Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts. The diameter of the vessel at the site of filter loop placement should be between 2.25 mm and 5.5 mm.

The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral, carotid, or peripheral vasculature.
The safety and effectiveness of the device as an embolic protection system has not been established in treating patients with acute myocardial infarction.
The safety and effectiveness of the device as an embolic protection system has not been established in treating native coronaries.

Device Description

The Boston Scientific FilterWire EZ (2.25 mm - 3.5 mm) Embolic Protection System is a temporary intra-vascular 0.014" guide wire filtration system that is placed distal to the vessel lesion to be treated by interventional procedures. The system consists of a Protection Wire (190 cm or 300 cm length), an EZ Delivery Sheath, an EZ Retrieval Sheath and accessories. The 190 cm long wire is compatible with the Boston Scientific Add Wire® Extension Wire (K970376 cleared June 6, 1997) for over-the-wire catheter exchanges. The Filter Wire EZ (2.25 mm - 3.5 mm) Protection Wire is delivered via the EZ Delivery Sheath. Once the Protection Wire is across the lesion, the filter bag is expanded in the artery lumen by removing the EZ Delivery Sheath. After treating the lesion, all interventional devices are removed, and the EZ Retrieval Sheath or EZ Bent Tip Retrieval Sheath is advanced to the proximal end of the filter and the filter loop is retracted into the EZ Retrieval Sheath, trapping any emboli caught during the procedure. The EZ Retrieval Sheath and EZ Protection Wire are then removed from the patient simultaneously.

AI/ML Overview

This document is a 510(k) premarket notification for the Boston Scientific FilterWire EZ™ Embolic Protection System (2.25 mm – 3.5 mm). The study described is not for an AI/ML device, but rather a traditional medical device. Therefore, much of the requested information (e.g., number of experts, adjudication methods, MRMC study, standalone performance, training set details) is not applicable.

However, based on the provided text, here is an analysis of the acceptance criteria and study that proves the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criterion (Primary Endpoint)	Reported Device Performance (BLAZE II)	Comparator Performance (FIRE Trial subset)	Outcome
30-day MACE rate of the FilterWire EZ (2.25 mm - 3.5 mm) System, demonstrating non-inferiority to the predicate device (GuardWire Plus).	3.8% (initial analysis)	12.4%	FilterWire EZ demonstrates superiority.
Revised 30-day MACE rate (imputing 1 additional patient for missing CK-MB data)	4.6% (6/131)**	12.4% (21/169)	FilterWire EZ demonstrates superiority and non-inferiority is achieved.
Device success	98.5%	Not explicitly stated for comparator	N/A
Clinical success	94.7%	Not explicitly stated for comparator	N/A
Final TIMI 3 flow	100%	Not explicitly stated for comparator	N/A

Note: The primary acceptance criterion for the clinical study was likely to demonstrate non-inferiority in the 30-day MACE rate compared to the predicate GuardWire Plus device in the specified vessel diameter range.

2. Sample Size and Data Provenance

Test Set (Clinical Study):
- FilterWire EZ Group (BLAZE II): 131 registry patients, 8 roll-in patients, 1 compassionate use patient (total 140 enrolled, but performance analysis focuses on "131 registry patients").
- GuardWire Plus Control Group (FIRE Trial subset): 169 patients treated within the 2.25 mm - 3.5 mm vessel diameter range.
Data Provenance: Prospective, multi-center study (BLAZE II) for the FilterWire EZ device. The comparator data (GuardWire Plus) was from a subset of a previously completed study (FIRE Trial). The countries of origin of the data are not explicitly stated, but it's a multi-center study.

3. Number of Experts and Qualifications

This information is not applicable as the submission describes a traditional medical device with a clinical trial, not an AI/ML device where expert consensus is typically used to establish ground truth for a test set.

4. Adjudication Method

This information is not applicable for a traditional clinical trial measuring clinical outcomes like MACE. MACE (Major Adverse Cardiac Events) are defined clinical endpoints.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

Not Applicable. This is a study for a traditional medical device (embolic protection system), not an AI/ML diagnostic or assistive device that would involve human readers.

6. Standalone Performance

Not Applicable. This device is an interventional tool, and its performance is inherently linked to human use during a procedure. "Standalone performance" as often understood for AI algorithms (i.e., algorithm only without human-in-the-loop) is not relevant here. However, the study focuses on the device's technical success, clinical success, and impact on patient outcomes (MACE) when used by clinicians.

7. Type of Ground Truth Used

Clinical Outcomes Data: The primary ground truth for the clinical study was the occurrence of Major Adverse Cardiac Events (MACE) at 30 days post-procedure, as well as device success, clinical success, and final TIMI 3 flow. MACE is a composite of clinically defined adverse events (e.g., all-cause death, myocardial infarction, target vessel revascularization). The presence of non-Q wave MI was assessed via CK-MB levels.

8. Sample Size for the Training Set

Not Applicable. This is not an AI/ML device that requires a "training set" in the context of machine learning. The device design and specifications are based on engineering principles and preclinical testing.

9. How the Ground Truth for the Training Set Was Established

Not Applicable. See point 8.

Summary

{0}------------------------------------------------

APR 1 0 2006

(This Summary is submitted in accordance with 21 CFR Part 807, Section 807.92)
--------------------------------------------------------------------------------

Submitter's Name:	Boston Scientific Corporation
Submitter's Address:	2011 Stierlin CourtMountain View, CA 94043-4655
Contact Person:	Debbie McIntireSenior Regulatory Affairs Specialist(650) 623-1703(650) 623-1610 FAXmcintird@bsci.com
Device Proprietary Name:	FilterWire EZ TM (2.25 mm – 3.5 mm) EmbolicProtection System
Device Common Name:	Embolic Protection Device
Device Classification Name:	21 CFR 870.1250, Percutaneous Catheter
Device Class:	Class II
Date Prepared:	July 15, 2005

Identification of Predicate Devices:

The Boston Scientific FilterWire EZTM (2.25 mm - 3.5 mm) Embolic Protection System is substantially equivalent in design and intended use to the FilterWire EZ (3.5 mm - 5.5 mm) Embolic Protection System legally marketed under K032884 and to the Medtronic® PercuSurge GuardWire Plus® Temporary Occlusion and Aspiration System (K013913) indicated in 2.5 -- 5.0 mm SVG vessel diameters.

Device Description:

Section 4

510(k) Summary

{1}------------------------------------------------

with the Boston Scientific Add Wire® Extension Wire (K970376 cleared June 6, 1997) for over-the-wire catheter exchanges.

The Filter Wire EZ (2.25 mm - 3.5 mm) Protection Wire is delivered via the EZ Delivery Sheath. Once the Protection Wire is across the lesion, the filter bag is expanded in the artery lumen by removing the EZ Delivery Sheath. After treating the lesion, all interventional devices are removed, and the EZ Retrieval Sheath or EZ Bent Tip Retrieval Sheath is advanced to the proximal end of the filter and the filter loop is retracted into the EZ Retrieval Sheath, trapping any emboli caught during the procedure. The EZ Retrieval Sheath and EZ Protection Wire are then removed from the patient simultaneously.

Indications for Use:

The Filter Wire EZ (2.25 mm - 3.5 mm) Embolic Protection System represents a product line extension to the commercially available FilterWire EZ (3,5 mm - 5,5 mm) Embolic Protection System (K032884), so the indications for use statement is similar to that already cleared under K032884 except the reference to the diameter of the vessel at the site of filter loop placement which covers the range from 2.25 mm to 3.5 mm. Please note the indications statement includes a change in phrasing to emphasize the intended vessel diameter range for filter loop placement, and that range will be inclusive of the predicate and subject devices range. The proposed Indications for Use statement is provided below:

"The FilterWire EZTM Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts. The diameter of the vessel at the site of filter loop placement should be between 2.25 mm and 5.5 mm.

. The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral, carotid, or peripheral vasculature.
. The safety and effectiveness of the device as an embolic protection system has not been established in treating patients with acute myocardial infarction.
The safety and effectiveness of the device as an embolic protection system has . not been established in treating native coronaries."

Summary of Technological Characteristics:

The Filter Wire EZ (2.25 mm - 3.5 mm) Embolic Protection System indicated for use in saphenous vein bypass grafts is equivalent to the Filter Wire EZ (3.5 mm - 5.5 mm) Embolic Protection System cleared under K032884 and the Medtronic® PercuSurge GuardWire Plus® (GuardWire Plus ) cleared under K013913 in that the intended use, principles of operation, design and materials are similar. The

* Also referred to as PercuSurge

{2}------------------------------------------------

following design attributes are the same or similar for the subject device and the identified predicate devices:

{3}------------------------------------------------

Predicate Devices		Subject Device
FilterWire EZ(3.5 mm - 5.5 mm) System	MedtronicGuardWire Plus	FilterWire EZ(2.25 mm - 3.5 mm) System
Single Operator Exchangedelivery systems	Same	Same
Filter-based technology	Balloon-based technology	Filter-based technology
Nitinol® filter/basketcomponent	Elastomeric OcclusionBalloon on Nitinol Hypotube	Nitinol® filter/basketcomponent
Polyurethane filtermembrane	Elastomeric OcclusionBalloon	Bionate™ polyurethane filtermembrane
Compatibility with .014"guide wires	Same	Same
Compatibility with 6F guidecatheters	Same	Same
Available in 2 lengths190cm or 300 cm lengths	Same	Same
Radiopaque guide wire tips	Same	Same
Radiopaque markers on filterloop	Contrast/Heparinized salinemixture in balloon	Radiopaque markers on filterloop

Performance Data:

Filter Wire EZ (2.25 mm - 3.5 mm) System in-vitro testing consisted of dimensional testing, tensile/torque testing and functional testing. Biocompatibility, packaging testing, product shelf life testing, functional testing in animal models and a clinical study in saphenous vein graft patients (G020229 - BLAZE II) have also been successfully conducted. In-vitro test results verified that the Filter Wire EZ (2.25 mm - 3.5 mm) Embolic Protection System met all applicable product specifications and is deemed adequate for its intended use.

Results from the BLAZE II study (EmBoLic Protection TrAnsluminally with the Filter Wire EZ DEvice in Saphenous Vein Grafts), designed to assess the Filter Wire EZ (2.25 mm - 3.5 mm) Embolic Protection System during percutaneous treatment of saphenous vein graft stenosis in terms of 30-day MACE rates validated the safety and effectiveness of the FilterWire EZ (2.25 mm -- 3.5 mm) System. These results were compared to the 30-day MACE results of a subset of GuardWire Plus patients from the FIRE Trial (K023691) (treated in the same vessel diameter range of 2.25 mm - 3.5 mm).

The BLAZE II study design was prospective, multi-center, and non-randomized. One-hundred thirty-one (131) registry patients, eight (8) roll-in patients and one (1) compassionate use patient were enrolled at 19 centers in this study. Clinical followup was performed 30 days post-procedure. The cumulative incidence of MACE at 30 days (primary endpoint) was 3.8% for the FilterWire EZ (2.25 mm - 3.5 mm) patients. The 30 day MACE results of the GuardWire Plus subset patients (treated in the same vessel diameter range of 2.25 mm - 3.5 mm) in the FIRE Trial was 12.4%.

{4}------------------------------------------------

The FilterWire EZ (2.25 mm - 3.5 mm) System demonstrated device performance with device success of 98.5%, clinical success of 94.7% and final TIMI 3 flow of 100%. Methods from the BLAZE II registry were analogous to the previously completed Randomized FIRE Trial (FilterWire EX / Medtronic GuardWire Plus) and the BLAZE study (Filter Wire EZ) with respect to enrollment criteria and primary endpoint.

Due to the non-randomized nature of group membership, adjusted one-sided and two-sided confidence intervals of the treatment difference in 30-day MACE rate were also calculated as follows. For each individual, a propensity score for group membership (FilterWire EZ™ (2.25 mm - 3.5 mm), PercuSurge) was calculated using logistic regression, with "group" as the outcome and baseline and predictor variables as independent variables. Patients were then categorized into quintiles based on this propensity score. An estimate of the overall treatment difference (and its confidence interval) across all propensity score quintiles, adjusted for propensity score quintile. was calculated. By this method we obtain an adjusted difference between FilterWire EZTM (2.25 mm - 3.5 mm) and PercuSurge on 30-day MACE rate of -4.4% with adjusted two-sided 95% CI of [-11.6%, 2.9%], and adjusted upper one-sided 95% CI of 1.8%, also supporting non-inferiority.

During conduct of the study, there were 40 BLAZE II patients who had at least one missing CK-MB result with the remaining CK-MB results being <3x normal range; there were 2 BLAZE II patients with missing CK-MB at all three time points (6-8. 12-16, and 18-24 hours post-procedure). To address this issue of missing CK-MB data, additional analysis on MACE was performed. In the primary analysis, these 42 patients were considered as not having non-Q wave MI since the majority of them had missing CK-MB due to being discharged early from the hospital because of no safety concerns. To estimate what the non-Q wave MI rate would have been for these patients had their missing CK-MB(s) been measured, the following analysis was performed. Data from FIRE, BLAZE and BLAZE II patients with non-missing CK-MB at all three time points (6-8, 12-16, and 18-24 hours post procedure) were used to statistically estimate, for each BLAZE II patient with missing CK-MB, the probability that at least one missing CK-MB was abnormal (>3x normal range). The probabilities were then summed to obtain an estimate of the number of missing CK-MB patients who would have had an abnormal CK-MB and hence non Q-wave MI. The resulting estimate was that no more than 1 of these 42 patients would have had non Q-wave MI and, hence, MACE. The following table displays the results of a revised MACE analysis where one additional patient is included in the BLAZE II MACE incidence.

As can be seen, there is no marked change in results from the primary analysis; i.e., non-inferiority to GuardWire Plus is still achieved.

{5}------------------------------------------------

Table 6. Revised MACE analysis imputing 1 additional patient.

	BLAZE II (N=131)	PercuSurge (N=169)*	Difference [95% C.I.]	Upper one-sided
MACE (to 30 days)	4.6% (6/131)**	12.4% (21/169)	-7.8% [-13.9%,-1.6%]	-2.7%
* Control group from FIRE trial with 2.25≤R VD≤3.5

** Included additional MACE based on predicted values for m issing CK-MB.

Statement of Substantial Equivalence

Based on a comparison of intended use, results of in-vitro testing, in-vivo testing, biocompatibility, packaging, and clinical evaluation, Boston Scientific considers the FilterWire EZ (2.25 mm - 3.5 mm) Embolic Protection System substantially equivalent to the legally marketed FilterWire EZ (3.5 mm - 5.5 mm) Embolic Protection System (K032884) and the Medtronic® PercuSurge GuardWire Plus® Temporary Occlusion and Aspiration System (K013913).

{6}------------------------------------------------

Image /page/6/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes representing the three levels of government: federal, state, and local. The eagle is encircled by the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA".

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 0 2006

Boston Scientific Corporation c/o Ms. Debbie McIntire Senior Regulatory Affairs Specialist 2011 Stierlin Court Mountain View, CA 94043-4655

Re: K051984

Trade/Device Name: FilterWire EZTM Embolic Protection System, sizes 2.25 - 3.5mm Regulation Number: 21 CFR 870.2350 Regulation Name: Distal Embolic Protection Guidewire Regulatory Class: Class II Product Code: NFA Dated: March 10, 2006 Received: March 13. 2006

Dear Ms. McIntire:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{7}------------------------------------------------

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Bran D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{8}------------------------------------------------

510(k) Number (if known)_KO519184

Device Name: FilterWire EZ™ (2.25 mm - 3.5 mm) Embolic Protection System

Indications for Use:

The safety and effectiveness of this device as an embolic protection system has not . been established in the cerebral, carotid, or peripheral vasculature.
The safety and effectiveness of the device as an embolic protection system has not . been established in treating patients with acute myocardial infarction.
The safety and effectiveness of the device as an embolic protection system has not . been established in treating native coronaries.

Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (Per 21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K05/984

April 2006

Regulation Number and Section

§ 870.1250 Percutaneous catheter.

(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).